Psyence Biomedical Ltd. PBM
5.56
(0.30)
(5.12%)
as of 25 Sep
- Market cap
- $22.4M
- P/E
- 0.2×
Follow PBM
| Dec '17 | Jan '21 | Jan '22 | Dec '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 14.17 | 0.08 | 0.09 | 0.09 | 11.04 | 14.62 |
Net Debt/EBITDA |
— | 1.94 | 0.10 | 0.28 | 0.28 | 1.69 | 1.20 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.10) | (0.06) | 0.00 | 0.06 | (3.69) | 1.17 |
Capex/Depreciation |
— | — | — | — | (28.50) | (2.30) | (0.04) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 3.33% | (54.66%) | 149.52% | (47.61%) | (58.62%) | |
| — | 6.42% | 3.11% | (39.34%) | (4,518.56%) | 23.95% | (55.75%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | (415.57%) | (41.24%) |
Return on Tangible Assets |
— | 909.94% | (61.34%) | 466.25% | 466.25% | 16.93% | (81.67%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | — | 0.00% |
Free Cash Flow per Share |
— | (0.03) | (0.02) | 0.00 | (1,735.94) | (121.17) | (14.74) |
Cash per Share |
— | 0.02 | 0.00 | 0.09 | 448.71 | 199.71 | 13.57 |
Shareholders Equity per Share |
— | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 |
Free Cash Flow |
— | (0.84) | (0.52) | — | (2.95) | (3.74) | (8.14) |
Working Capital |
— | 0.90 | (13.07) | (10.98) | (10.98) | 5.97 | 8.49 |
Capital Expenditures |
— | — | — | — | (0.01) | (0.01) | 0.00 |
Net Current Asset Value |
— | (18.61) | (13.07) | (10.98) | (10.98) | 5.97 | 8.49 |
| Other line items | |||||||
Quick Ratio |
— | 9.44 | 0.07 | 0.07 | 0.07 | 10.61 | 12.60 |
Depreciation/Fixed assets |
— | — | — | 0.00 | 0.04 | 0.39 | 0.87 |
Cash ROIC |
— | (0.35%) | (0.21%) | 0.05% | 28.90% | (29.05%) | (33.35%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
— | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.03) | (0.02) | 0.00 | (1,732.59) | (120.85) | (14.74) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (3.35) | (0.32) | 0.00 |
Average Receivables |
— | — | — | 0.44 | 0.04 | 0.09 | 0.25 |
Average Payables |
— | — | — | — | — | 0.57 | 0.40 |
Average Assets |
— | 128.11 | 257.58 | 130.03 | 1.13 | 4.22 | 12.44 |
Average Common Equity |
— | — | 240.65 | 93.60 | (34.22) | (2.13) | 11.83 |
Capex to Sales |
— | — | — | — | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates